Last 29 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.64 | — | — | — | — | — | 0.03 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5373.68 | — | 42.45 | — | 557.32 | — | 524.54 | — | 314.16 | 1817.69 | 9441.22 | 12092.06 | 972.74 |
| — | — | -91.9% | — | +77.4% | — | -94.4% | — | -67.7% | +188.2% | +5959.7% | +4991.1% | +554.9% | |
| P/B Ratio | 8.03 | 14.15 | 3.22 | 2.29 | 1.67 | 1.36 | 0.96 | 164.87 | 47.20 | 6.68 | — | 54.34 | 18.36 |
| — | +942.8% | +236.6% | -98.6% | -96.5% | -79.7% | — | +203.4% | +157.0% | — | — | +71.0% | -42.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | -0.00 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -1042.5% | — | 49.1% | — | -589.0% | — | 100.0% | — | 81.8% | 100.0% | -883.3% | -4147.1% | -162.8% |
| — | — | -50.9% | — | -820.4% | — | +111.3% | — | +150.2% | +163.0% | +78.5% | -4247.1% | -262.8% | |
| Operating Margin | -165724.0% | — | -2106.8% | — | -49928.0% | — | -160898.0% | — | -5403.2% | -38510.1% | -137796.7% | -257447.1% | -12956.2% |
| — | — | +98.7% | — | -824.0% | — | -16.8% | — | +58.3% | -256.8% | -2731.8% | -8018.1% | -1793.6% | |
| Net Margin | 843786.0% | — | -2204.2% | — | -47865.0% | — | 1858011.0% | — | -5728.5% | -43520.2% | -156840.0% | -286417.6% | -14932.5% |
| — | — | -100.1% | — | -735.6% | — | +1284.7% | — | +61.6% | -197.7% | -2855.4% | -7725.2% | -1898.6% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1905.9% | -66.9% | -35.2% | -38.0% | -30.7% | -22.1% | 1609.1% | -285.8% | -108.2% | -98.9% | — | -133.1% | -355.7% |
| — | -203.4% | -102.2% | +86.7% | +71.6% | +77.7% | — | -114.8% | +69.6% | — | — | -58.4% | -576.3% | |
| ROA | 690.7% | -18.1% | -12.6% | -20.5% | -23.7% | -18.2% | 679.4% | -26.4% | -27.5% | -17.7% | -20.2% | -17.9% | -18.0% |
| — | +0.8% | -101.9% | +22.5% | +13.7% | -3.2% | +3470.5% | -47.6% | -53.2% | +22.1% | +5.3% | +16.8% | -18.5% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.19 | 1.56 | 1.13 | 0.06 | 0.01 | 0.01 | 18.23 | 4.83 | 1.60 | — | 13.61 | 3.57 |
| — | +1745.3% | +15638.3% | -93.8% | -98.8% | -99.4% | — | +34.0% | +35.4% | — | — | +222.4% | +159.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.94 | 4.49 | 4.98 | 5.12 | 3.94 | 4.70 | 6.20 | 3.82 | 5.25 | 10.16 | 6.49 | 7.47 | 10.17 |
| — | -4.6% | -19.6% | +34.0% | -24.9% | -53.7% | -4.5% | -48.9% | -48.4% | +68.0% | -13.5% | -0.2% | +64.2% | |
| Quick Ratio | 3.94 | 4.49 | 4.98 | 5.12 | 3.94 | 4.70 | 6.20 | 3.82 | 5.25 | 10.17 | 6.49 | 7.48 | 10.17 |
| — | -4.6% | -19.6% | +34.0% | -24.9% | -53.7% | -4.5% | -48.9% | -48.4% | +67.8% | -13.5% | +4.0% | +63.2% | |
| Interest Coverage | -24.57 | -10.63 | -8.72 | -15.95 | — | — | -30.01 | -9.08 | -10.74 | -5.62 | -5.23 | -8.62 | -6.64 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonInhibrx Biosciences, Inc.'s current P/E is 0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Inhibrx Biosciences, Inc.'s current operating margin is -165724.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Inhibrx Biosciences, Inc.'s business trajectory between earnings reports.